Research progress of relevance between cholecystokinin and depression

doi:10.12092/j.issn.1009-2501.2021.06.010

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (6): 672-679.doi: 10.12092/j.issn.1009-2501.2021.06.010

Previous Articles Next Articles

Research progress of relevance between cholecystokinin and depression

WANG Yeqing ¹, WANG Yuhong ¹, LIU Jian ², ZHAO Hongqing ¹, ZOU Manshu ¹

¹ Institute of Innovation and Applied Research, Hunan University of Chinese Medicine, Changsha 410208, Hunan, China; ²The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, Hunan, China

Received:2020-11-02 Revised:2021-05-17 Online:2021-06-26 Published:2021-07-06

Abstract

Abstract: Depression is a mental illness characterized by significant and lasting depression. Recent studies have found that cholecystokinin, as a small brain-gut peptide molecule, is widely distributed in the central nervous system and enteric nervous system. In order to further clarify the relationship between CCK and the pathogenesis of depression, this article reviews the effect of CCK in depression, including HPA axis, synaptic function and circuit mechanism, etc.

Key words: depression, cholecystokinin, neurons, mechanism

CLC Number:

R964
R965

WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.

[1]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[2]	ZHANG Wei, WANG Yingbin, CAO Lu, LIU Yan, ZHANG Li, LIU Jieting. Research progress of autophagy in intestinal ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1061-1066.
[3]	HE Teng, XU Xiangyang, XU Xiangqing, LIU Cunming, YANG Chun. Ketamine for depression treatment: past, present, and future [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1125-1132.
[4]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[5]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[6]	GE Wei, SHENG Wenyan, XU Qibing, LI Qiushi, SU Lingya, WU Shuangqing. Effects of SSRI antidepressant sertraline on ocular surface function in patients with postpartum depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 440-446.
[7]	FENG Rui, ZHANG Jiali, HE Mingchao, LI Yue, ZHANG Yan. Pharmacological targets and clinical application of traditional Chinese medicine and active components in the prevention and treatment for depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 467-474.
[8]	PAN Yalan, YUAN Wenchao, MA Yong, GUO Yang, ZHENG Suyang, XU Guihua, LIU Jiahuan. Effect of JiSuiKang on the microglia infiltration and neuron survival in the spinal cord injury area of rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 151-158.
[9]	WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin. Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1070-1074.
[10]	ZHOU Yancan. Effects of agomelatine on depressive disorder and brain-derived neurotrophic factor ZHOU Yancan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 699-703.
[11]	CHEN Lianzhou, LI Songhua, PU Ben. Effects of aripiprazole combined with escitalopram oxalate on DA, 5-HT and cortisol in patients with severe depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 446-450.
[12]	CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.
[13]	WANG Rouxin, FANG Zekang, YAO Siqi, XUE Yingying, ZHAO Yeying, YE Yilu. Effects of nicotinamide ribose on adolescent depression rats after neonatal maternal deprivation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1015-1021.
[14]	WU Mengyao, ZHAO Hongqing, WANG Yuhong. Advances of the ion channels related to depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 949-954.
[15]	XU Wei, QU Weimin, HONG Zongyuan. Advances in research on the mechanism of general anesthesia by specific manipulation of neuron activities [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 825-829.

Research progress of relevance between cholecystokinin and depression

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments